Event context and what is moving Boston Scientific today

Boston Scientific (BSX) is back on investors’ radar after recent share price swings, with the stock up about 1.3% on the day but showing mixed performance over the past month and past 3 months.

With the share price at US$92.51, Boston Scientific has a 1 day share price return of 1.34% and a year to date share price return showing a 2.32% decline. The 1 year total shareholder return shows a 9.25% decline, which contrasts with gains of 101.50% over 3 years and 161.03% over 5 years. This points to long term momentum alongside more recent cooling as investors reassess growth prospects and risks.

If this type of move has you looking across the sector, it could be a useful moment to scan other healthcare stocks that might fit your watchlist next.

With the shares sitting below some analyst targets and recent returns cooling after strong multi year gains, the key question now is whether Boston Scientific still trades at a discount or if the market already prices in its future growth.

Most Popular Narrative: 26.3% Undervalued

At $92.51, Boston Scientific sits well below the most followed fair value estimate of about $125.45, which leans heavily on long term growth assumptions and higher future profitability.

Investment in proprietary, high margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.

Want to see what kind of revenue runway and profit lift this story is built on? The narrative leans on disciplined growth, richer margins, and a punchy earnings multiple. Curious which specific financial levers have to click into place to bridge today’s price to that fair value?

Result: Fair Value of $125.45 (UNDERVALUED)

However, there are still real pressure points, including tariff costs and tougher reimbursement decisions, that could cap margins and challenge the optimistic earnings path reflected in this story.

Another View: What The P/E Says

That 26.3% undervalued fair value is not the only story. On a P/E of 49.2x, Boston Scientific trades above the US Medical Equipment industry at 32x, peers at 41.7x, and even its own fair ratio of 41x, which signals richer pricing. So is this a quality premium or valuation risk in your book?

Build Your Own Boston Scientific Narrative

If you look at the numbers and come to a different conclusion, or prefer to test your own view, you can build a personalised narrative in a few minutes with Do it your way.

A great starting point for your Boston Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Boston Scientific has you thinking harder about where to put your capital next, do not stop here. Your next strong idea could be one screen away.

• Spot companies the market may be overlooking by scanning these 874 undervalued stocks based on cash flows built around cash flow focused opportunities.
• Zero in on income potential by checking out these 13 dividend stocks with yields > 3% that meet a yield threshold above 3%.
• Get ahead of emerging themes by reviewing these 24 AI penny stocks that are tied to artificial intelligence trends.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.